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Abstract
Background: In solid organ transplant (SOT) recipients, transplant rejection during immune checkpoint inhibitor
(ICI) treatment for cancer is a clinical problem. Donor-derived cell-free DNA (dd-cfDNA) can be detected in blood
and is a sensitive biomarker for diagnosis of acute rejection in SOT recipients. To our best knowledge, this is the
first case report of a kidney transplant recipient with advanced cancer treated with ICI who was monitored with
dd-cfDNA.
Case presentation: A 72-year old female with a long-standing renal transplant was diagnosed with advanced
melanoma in 2018 and was treated with the anti-PD1 antibody nivolumab. Within 12 days after the first administration
of nivolumab, dd-cfDNA ratio increased to 23%, suggesting allograft rejection. Her kidney transplant function
deteriorated and acute rejection was confirmed by renal transplant biopsy. As the rejection could not be
controlled despite immunosuppressive treatment, a transplant nephrectomy was necessary and haemodialysis
was started. Immunological analysis of the renal explant showed infiltration of alloreactive, nivolumab-saturated, PD1+
cytotoxic T cells. After transplant nephrectomy, she experienced nivolumab-related toxicity and rapid disease
progression.
Conclusion: Clinicians prescribing ICIs should be aware that SOT recipients are at risk of transplant rejection
as a result of T cell activation. Dd-cfDNA is a sensitive biomarker and should be further studied for early detection of
transplant rejection. Immunological analysis of the kidney explant showed marked graft infiltration with alloreactive PD-
1+ cytotoxic T cells that were saturated with nivolumab.
Keywords: Allograft rejection, Anti-PD-1, Dd-cfDNA, Melanoma, Donor-derived cell-free DNA, Immune checkpoint
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Background
Immune checkpoint inhibitors (ICIs) have significantly
improved the overall survival of patients with advanced
malignancies, including advanced stage melanoma [1].
The monoclonal antibody nivolumab blocks the inhibitory
immune checkpoint receptor programmed death-1 (PD-
1), thereby promoting the anti-tumor immune response
[2]. This is particularly hazardous for solid organ trans-
plant (SOT) recipients who may develop acute rejection
as a result of enhanced T cell activation [3]. As SOT recip-
ients have an increased risk to develop ICI-responsive ma-
lignancies, including melanoma and cutaneous squamous
cell carcinoma [4, 5], ICI-induced SOT rejection is a clin-
ical problem. For adequate patient counselling and early
intervention during ICI treatment, biomarkers for early
detection of acute rejection are needed. However,
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conventional biomarkers to monitor SOT integrity have a
low sensitivity and specificity [6].
Donor-derived cell-free DNA (dd-cfDNA) can be de-
tected in blood and urine of SOT recipients and has been
shown to be a potentially useful biomarker for the early
diagnosis of acute rejection of kidney transplants [7]. In
kidney transplant recipients, dd-cfDNA levels of < 1% of
total cfDNA appear to reflect the absence of active rejec-
tion whereas levels > 1% seem to indicate active rejection
[7]. However, many questions regarding the clinical utility
of dd-cfDNA monitoring following SOT remain and this
is not standard practice (reviewed in Verhoeven et al.) [7].
Here, a kidney transplant recipient is described who expe-
rienced severe acute allograft rejection during ICI therapy
for metastatic melanoma. In the current analysis, dd-
cfDNA was evaluated as a potential sensitive biomarker
for detection of transplant rejection in a cancer patient
treated with ICIs. Second, to understand the pathophysi-
ology of this ICI-induced rejection, graft-infiltrating leuco-
cytes were isolated and characterized.
Case presentation
In 2018, a 72-year-old female with a long-standing renal
transplant was diagnosed with metastatic BRAF-wildtype
melanoma, 5 years after a cutaneous melanoma (Breslow
thickness 0.8 mm) had been radically excised. She pre-
sented with a solitary large left axillary metastasis of 6
cm which encased the axillary artery and the plexus bra-
chialis, resulting in edema and paralysis of her left arm.
The patient had received a deceased donor kidney trans-
plant in 2013 due to end-stage renal disease caused by
hypertensive nephropathy and a unilateral nephrectomy
because of renal cell carcinoma (T2N0M0) in 2006.
Apart from the development of post-transplantation dia-
betes mellitus, the clinical course after her transplant-
ation had been uneventful. At the time of melanoma
diagnosis, she had a stable renal function with limited
proteinuria (urinary protein to creatinine ratio of 33 g/
mol) and a serum creatinine concentration of 150 umol/
L, corresponding to an eGFR of 30 mL/min per 1.73 m2
(CKD-EPI formula) [8].
The large left axillary mass was considered unresect-
able. After radiotherapy combined with hyperthermia,
she had progressive disease with pulmonary and distant
lymph node metastases. She was carefully counselled
about ICI-associated side effects, specifically about the
possibility of renal allograft rejection. Progressive axillary
metastasis with severe vascular and neurologic compli-
cations led to the shared decision to start first-line
nivolumab (3 mg/kg Q2W). The immunosuppressive
regimen consisting of tacrolimus (1.5 mg q.d.) and myco-
phenolate mofetil (500 mg b.i.d.) was switched to pred-
nisolone (20 mg q.d.) and nivolumab was administered 1
week thereafter.
Twelve days after first nivolumab administration, the
patient presented with nausea, vomiting, loose stools
and abdominal pain located at the site of her transplant.
Laboratory investigation demonstrated severe renal in-
sufficiency with a serum creatinine of 549 umol/L. A
kidney transplant biopsy was performed and demon-
strated extensive acute ischemic changes with capillary
endothelial necrosis, tubular epithelial degeneration,
edema and haemorrhage, consistent with infarction
(Fig. 3a). These findings were interpreted as acute kidney
transplant rejection and methylprednisolone pulse ther-
apy (1000 mg intravenously for 3 consecutive days) and
haemodialysis were initiated. Because of ongoing rejec-
tion despite methylprednisolone treatment, prednisolone
was discontinued and transplant nephrectomy was per-
formed. Because of advanced malignancy, T lymphocyte-
depleting antibodies were not administered.
After transplant nephrectomy, nivolumab was contin-
ued for a period of 8 weeks. As she experienced
immune-related adverse events, including pneumonitis
grade 2 and colonoscopy-conformed colitis grade 2
(common terminology criteria for adverse events version
4.03), nivolumab was discontinued and prednisolone was
initiated. Three months after the start of nivolumab, 18F-
FDG PET-CT revealed progressive disease with new
lung and lymph node metastases (Fig. 1). The patient de-
cided to stop haemodialysis and died 5 months after the
start of nivolumab.
Dd-cfDNA reveals acute allograft rejection
The patient participated in the MULTOMAB clinical
trial, (see Dutch Trial Register number NTR7015), in
which blood is collected prospectively for translational
purposes. After kidney transplant rejection, previously
obtained blood samples were analyzed for dd-cfDNA.
Dd-cfDNA was expressed as a percentage of total
cfDNA (see Methods section below). Prior to adminis-
tration of nivolumab, dd-cfDNA was low (0.9%; Fig. 2).
One week after administration of nivolumab, dd-cfDNA
increased to 2.9%, indicating active rejection of the
allograft. At the time of rejection, 12 days after first
administration of nivolumab, dd-cfDNA increased to a
maximum of 23.1%. Dd-cfDNA levels declined to 8.8,
0.1 and 0.0% at 3–5 h, 22 days and 77 days after trans-
plant explantation, respectively, corresponding with the
half-life of dd-cfDNA [9].
Acute vascular rejection with viable graft infiltrating
lymphocytes
Histopathological examination of the explanted kidney
allograft demonstrated severe vascular, acute T-cell medi-
ated rejection with an almost entirely necrotic kidney par-
enchyma with hemorrhage and moderate endothelialitis
with focal fibrin deposition (Fig. 3b). CD3+ T lymphocytes
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Fig. 1 18F-FDG PET-CT revealed progressive disease at three months after start of nivolumab, with new lung and lymph node metastases. Pleural
effusion was present
Fig. 2 Time course of the percentage plasma dd-cfDNA (in green) and serum creatinine concentration (in red), in relation to important clinical
events. During the hospital admission, hemodialysis (HD; day 17) was initiated. Dd-cfDNA levels declined from 23 to 8.8% 3–5 h after kidney
explantation. Dotted lines are added to connect separate measurements of creatinine and dd-cfDNA. Of note, no comparative serum creatinine
measurement was performed at 7 days after the first administration of nivolumab
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were found subendothelially (Fig. 3c) and included both
CD4+ (Fig. 3d) and CD8+ T cells (Fig. 3e). No CD20+ B
lymphocytes were identified (Fig. 3f). The cytotoxic CD8+
T cells were active and viable, as evidenced by the pres-
ence of intracellular granzyme B (Fig. 3g) and Ki-67
(Fig. 3h), reflecting their cytotoxic potential and prolifera-
tion, respectively. PD-1+ staining was also seen in the
vessel wall (Fig. 3i).
Despite the necrotic status of the renal explant, viable
lymphocytes were revealed, which mainly consisted of
CD3+ T cells (59%). Within the total CD3+ T cell popu-
lation, the CD4+:CD8+ ratio was approximately 1:3 (22%
CD4+ and 73% CD8+, Fig. 4a). Cytokines, such as IFN-y,
TNF and IL-2, play an important role in the immune re-
sponse that mediate allograft rejection. The amount of
these pro-inflammatory cytokines, produced by T-cells,
indicates whether these cells are activated. After poly-
clonal stimulation, the capacity of the T cells to produce
IFN-γ, TNFα and IL-2 was measured [10]. CD8+ T cells
had a higher capacity than CD4+ T cells to produce IFN-
γ (91% vs. 37%; Fig. 4b) and TNFα (66% vs. 34%),
whereas CD4+ T cells showed a higher capacity for IL-2
production (5% vs. 17%).
Nivolumab PD-1 occupancy on graft infiltrating
lymphocytes
Further immunological analysis was performed to exam-
ine whether nivolumab was successfully bound to the
graft infiltrating lymphocytes (GILs), which were consid-
ered to have caused rejection. Among the GILs, PD-1
was expressed on both the CD4+ and CD8+ T cells (31
and 34%, respectively; Fig. 4c), indicating that the recep-
tor for nivolumab was present on the surface of these
cells. To determine the amount of free PD-1 binding
places on the GILs in the explant, conjugated nivolumab
was added to the explant of both the current and a con-
trol patient, who experienced an acute rejection without
ICI. In the renal explant of the control patient, nivolu-
mab binding capacity was 49% of CD4+ and 37% CD8+
T-cells (Fig. 4d), whereas conjugated nivolumab was not
able to bind CD4+ and CD8+ T-cells (0 and 0%, respect-
ively) in the nivolumab-treated patient.
Discussion and conclusion
Here a melanoma patient with a kidney transplant is re-
ported who developed a fulminant acute kidney allograft
rejection 2 weeks after the start of nivolumab treatment.
Fig. 3 Histology of the renal graft at the time of the kidney transplant biopsy and the explantation under nivolumab treatment (250 μm scale
bar). Immunohistochemistry of the explanted kidney. a HE staining of the kidney biopsy shows diffuse cortical necrosis, hemorrhage and
glomerular congestion. b HE staining of the renal explant shows moderate endothelialitis with focal fibrin deposition. c-i immunohistochemistry of the
explanted kidney. c-e CD3+, CD4+ and CD8+ T-cells are present. f no CD20+ B-cells are present. g and h indicates the presence granzyme producing
cells and proliferating cells (Ki-67) cells. Overall, there is influx of PD-1+ granzyme B-producing CD8+ T-cells in the vascular wall with endothelialitis.
Magnification: 10x
Hurkmans et al. Journal for ImmunoTherapy of Cancer           (2019) 7:182 Page 4 of 7
Dd-cfDNA was measured in this cancer patient to moni-
tor allograft integrity and detect potential allograft rejec-
tion at an early stage during treatment with an ICI.
Previously, it has been reported that quantification of so
called dd-cfDNA can be useful to detect allograft rejec-
tion. Cell-free DNA is degraded into non-encapsulated
DNA and released after cell death, or by active secretion
of cells. During SOT rejection, the cells of donor origin
are damaged and their content is released into the
bloodstream. [7] Detection of dd-cfDNA is based on chi-
merism: donor cells are genetically distinct from that of
the transplant recipient [6].
Immunological analysis of the kidney explant showed
marked graft infiltration with alloreactive PD-1+ cyto-
toxic T cells that were saturated with nivolumab, demon-
strating nivolumab-mediated inhibition of PD-1. This
indicated that nivolumab was bound to the T cells which
likely caused allograft rejection. The graft infiltrating T
cell population had the capacity to mount an effector
response.
As indications of ICIs are expected to expand and
SOT recipients have an increased risk to develop ma-
lignancies, e.g. advanced hepatocellular carcinoma in
liver transplant patients, the use of ICIs in SOT re-
cipients is a clinical problem, the magnitude of which
is likely to increase in the near future [11]. However,
clinical trials of ICIs excluded SOT patients. Apart
from case reports and case series [12–16], the efficacy
and toxicity of ICI in transplanted patients with ma-
lignancies have not been studied extensively but do
indicate the high risk of allograft rejection. Serum
creatinine, which estimates the glomerular filtration
rate, is not specific nor sensitive for kidney transplant
rejection [17].
Fig. 4 Phenotyping of the graft infiltrating lymphocytes isolated from the explanted kidney during nivolumab treatment. a Unstimulated graft
infiltrating-lymphocytes were gated by size and granularity in the forward and side scatter. CD4+ and CD8+ T cells were gated within total CD3+
cells. b Intracellular IFN-γ, TNFα and IL-2 was determined in CD3+CD8− (representing the CD4+ population) and CD8+ T cells at 3 h of stimulation
with PMA/ionomycin. c Presence of the presence of PD-1 in CD4+ and CD8+ T-cells was also determined. d Blockade of the PD-1 receptor by
nivolumab was demonstrated by adding conjugated nivolumab to these cells and was compared with graft infiltrating lymphocytes of a rejected
kidney from a patient who was not treated with nivolumab
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The findings of the present case study suggest that dd-
cfDNA may be a valuable biomarker for early detection
of ICI-induced transplant rejection. It remains unclear at
this stage if this novel biomarker outperforms conven-
tional biomarkers such as serum creatinine. The first
serum creatinine measurement in this case was only per-
formed 12 days after the first administration of nivolu-
mab and not at the same time of the dd-cfDNA
measurement.
In conclusion, physicians prescribing ICIs should be
aware of the increased risk of allograft rejection as a
result of T cell activation. We believe that a com-
bined measurement of dd-cfDNA and conventional
biomarkers may assist physicians to diagnose trans-
plant rejection in this particular setting at an early
stage but this should be studied prospectively. The
transplant rejection was caused by alloreactive cyto-
toxic T cells that were positive for PD-1 and were
saturated with nivolumab, which is in line with the
anti-tumor effect of this drug.
Methods
Genotyping, isolation and measurement of dd-cfDNA
Peripheral blood mononuclear cells of the recipient and
spleen cells of the donor were used for automated purifi-
cation of DNA (Maxwell, Promega, Leiden, the
Netherlands). Donor and recipient were genotyped and
discriminated by using a panel of 10 preselected differ-
ent single-nucleotide polymorphisms (SNP). Blood sam-
ples for dd-cfDNA were collected in CellSave BCT tubes
(Menarini, San Diego, CA). Blood collection tubes were
stored at 4 °C within 3 h after collection, and within 2
days post draw, plasma was separated by centrifugation
at 1600×g for 20 min and stored at − 80 °C. Post thaw,
plasma was centrifuged for a second time at 16,000×g
for 10 min and cfDNA was extracted immediately using
the Circulating Nucleic Acid kit (Qiagen, Venlo, The
Netherlands)). For the droplet digital PCR (ddPCR),
droplets were manually generated with the QX200
Droplet Generator (Bio-Rad, Lunteren, The Netherlands)
. The samples were run on a the T100™ Thermal Cycler
(Biorad, Lunteren, The Netherlands). Dd-cfDNA was
quantified based on differences in SNPs between donor
and recipient (3 different SNPs that were able to distin-
guish between ddcfDNA and cfDNA) using the QX200™
Droplet Reader (Biorad, Lunteren, The Netherlands).
Analysis was performed with QuantaSoft Analysis Pro
(Bio-Rad, Lunteren, The Netherlands).
Immunohistochemical stainings
Four μm sections of Formalin-Fixed Paraffin-Embedded
(FFPE) tissue were mounted serially on adhesive glass
slides and deparaffinized. Antigen retrieval was per-
formed by CC1 antigen retrieval solution (ref. 950–124,
Ventana Medical Systems, Inc., Oro Valley, Arizona).
Specimens were incubated with the primary antibody.
The following antibodies were used; CD3 (ref. 790–4341,
Ventana Medical Systems, Inc., Oro Valley, Arizona),
CD4 (ref. 790–4423, Ventana Medical Systems, Inc., Oro
Valley, Arizona), CD8 (ref. 790–4460, Ventana Medical
Systems), CD20 (790–2531 Ventana Medical Systems),
Granzyme B (262R-18, Cell Marque Corporation, Rock-
lin, California), Ki-67 (ref. 790–4286 Ventana Medical
Systems) and PD-1 (ref. 760–4895, Cell Marque). Detec-
tion was performed with OptiView DAB (ref. 760–700,
Ventana Medical Systems, Inc.) or UltraView-DAB (ref.
760–500, Ventana Medical Systems, Inc) and amplifica-
tion was done with the Amplification Kit (ref: 760–080
or OptiView Amplification Kit ref.: 760–099, Ventana
Medical Systems, Inc.). Next, the specimens were coun-
terstained with haematoxylin II (ref: 790–2208, Ventana
Medical Systems, Inc.) and cover-slipped in order to
keep the specimens pressed flat. Each slide contained a
positive control. All stainings were performed on the
VENTANA BenchMark ULTRA (Ventana Medical
Systems, Inc.).
Flow cytometric phenotyping of graft infiltrating
lymphocytes (GILs)
GILs were stained with the following monoclonal anti-
bodies (MoAb) in order to determine their phenotype:
CD3, CD4, CD8, and PD-1. In order to measure the cap-
acity of the cells to produce pro-inflammatory cytokines,
the GILs were stimulated for 4 h with 0.5 μg/mL phorbol
myristate acetate (PMA) and 10 μg/mL ionomycin
(Sigma-Aldrich, St. Louis, MO) at 37 °C. Intracellular ac-
cumulation of cytokines was enhanced by the addition
of monensin and brefeldin A. The reaction was stopped
by the addition of ethylene-diamine-tetra-acetic acid.
Subsequently, cells were stained with CD3 brilliant violet
510 (BV510; Biolegend, San Diego, CA), CD4 brilliant
violet 421 (BV421; Biolegend), CD8 phycoerythrin-
cyanine7 (Pe-Cy7; BD), PD-1 allophycocyanin-Cy7
(APC-Cy7; Biolegend), and the viability marker 7-
aminoactinomycin (7-AAD; Biolegend). After surface
staining, the cells were immediately fixed with FACS lys-
ing solution (BD) and permeabilized with PERM II (BD).
Intracellular staining was performed with the following
MoAb: TNFα PE (Biolegend), IFNγ fluorescein isothio-
cyanate (FITC; BD) and IL-2 APC (BD). Samples were
measured on the FACSCanto II (BD).
In order to determine free binding places of nivolumab
(Bristol-Myers Squibb, New York, NY), was labelled with
the SiteClick™ R-PE Antibody Labeling Kit (ThermoFisher,
Waltham, MA). The GILs from the patient and the control
patient were not stimulated. Cells were phenotyped with
the following monoclonal antibodies: CD3 brilliant violet
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510 (Biolegend), CD4 brilliant violet 421 (Biolegend), CD8
phycoerythrin-cyanine7 (BD), Nivolumab-PE, and the via-
bility marker 7-aminoactinomycin (Biolegend). After sur-
face staining, the cells were measured on the FACSCanto II
(BD). Analysis was performed with Kaluza 1.5a software
(Beckman Coulter, Brea, CA).
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